{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"95.0","upperLimit":"99.8","value":"98.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"In Part I participants received open label 4 mg/kg canakinumab subcutaneous injection every 4 weeks for up to 32 weeks. For the first 8 weeks Part Ia (4 weeks) and Ib (4 weeks) patients maintained a stable oral steroid dose (prednisone or equivalent) followed by Ic an up to 20 week steroid tapering period and then Id a 4 week stable steroid dose period. Participants were then randomized to receive either 4 mg/kg canakinumab subcutaneous injection or Placebo comparator in Part II and remained on the stable oral steroid dose for 24 weeks. At 24 weeks in Part II participants with a \\>0.2 mg/kg and ≤ 0.5 mg/kg and no flare could restart steroid tapering. If the steroid dose was ≤ 0.2 mg/kg participants continued to maintain their current dose for the remainder of Part II.","id":"OG000","title":"Canakinumab"}],"paramType":"NUMBER","populationDescription":"Participants from the Full Analysis Set Part I with temperature readings at Day 3.","reportingStatus":"POSTED","timeFrame":"Day 3","title":"Part I: Percentage of Participants With Body Temperature ≤ 38 Degrees Celsius at Day 3 in Part 1a","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}